Literature DB >> 2964513

Topography of nerve cell loss from the locus caeruleus in middle aged persons with Down's syndrome.

B Marcyniuk1, D M Mann, P O Yates, C R Ravindra.   

Abstract

A topographical analysis of nerve cell loss from the locus caeruleus in middle aged patients with Down's syndrome (whose brains show the pathological changes of Alzheimer's disease), has shown that cell loss is confined to dorsal areas, being least most rostrally and greatest caudally. By contrast, there is no significant cell loss from ventral parts of the locus, at any point along its rostrocaudal length. Dorsally located neurones of the locus project to cerebral cortex; ventrally located neurones to non-cortical areas such as basal ganglia, cerebellum and spinal cord. These data suggest that the damage to nerve cells of the locus caeruleus in Down's syndrome at middle age, like that seen in Alzheimer's disease itself, relates to primary pathological events within the cortical projection fields of affected cells with perikaryal loss following on as a later change.

Entities:  

Mesh:

Year:  1988        PMID: 2964513     DOI: 10.1016/0022-510x(88)90016-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

1.  Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Authors:  Sarah B Martin; Amy L S Dowling; Joann Lianekhammy; Ira T Lott; Eric Doran; M Paul Murphy; Tina L Beckett; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease.

Authors:  D M Mann; D Jones; D Prinja; M S Purkiss
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

3.  Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled β2-adrenergic signaling.

Authors:  Keith Schutsky; Ming Ouyang; Steven A Thomas
Journal:  Learn Mem       Date:  2011-08-30       Impact factor: 2.460

Review 4.  Neuromodulatory signaling in hippocampus-dependent memory retrieval.

Authors:  Steven A Thomas
Journal:  Hippocampus       Date:  2015-04       Impact factor: 3.753

5.  Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease.

Authors:  Alain D Dekker; Yannick Vermeiren; Maria Carmona-Iragui; Bessy Benejam; Laura Videla; Ellen Gelpi; Tony Aerts; Debby Van Dam; Susana Fernández; Alberto Lleó; Sebastian Videla; Anne Sieben; Jean-Jacques Martin; Rafael Blesa; Juan Fortea; Peter P De Deyn
Journal:  Alzheimers Dement (Amst)       Date:  2017-11-23

6.  Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging.

Authors:  Nathan Duval; Guido N Vacano; David Patterson
Journal:  Front Aging Neurosci       Date:  2018-09-06       Impact factor: 5.750

7.  The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome.

Authors:  Yvonne S Davidson; Andrew Robinson; Vee P Prasher; David M A Mann
Journal:  Acta Neuropathol Commun       Date:  2018-07-04       Impact factor: 7.801

8.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

9.  Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models.

Authors:  Alain D Dekker; Yannick Vermeiren; Christelle Albac; Eva Lana-Elola; Sheona Watson-Scales; Dorota Gibbins; Tony Aerts; Debby Van Dam; Elizabeth M C Fisher; Victor L J Tybulewicz; Marie-Claude Potier; Peter P De Deyn
Journal:  Neurobiol Dis       Date:  2017-06-15       Impact factor: 5.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.